Applied Therapeutics, Inc. (APLT)
NASDAQ: APLT · Real-Time Price · USD
9.43
+0.50 (5.60%)
Nov 20, 2024, 4:00 PM EST - Market closed
Applied Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Revenue | -0.21 | 9.99 | - | - | - | - | |
Cost of Revenue | 52.35 | 53.91 | 55.63 | - | - | - | |
Gross Profit | -52.56 | -43.91 | -55.63 | - | - | - | |
Selling, General & Admin | 39.72 | 20.62 | 27.32 | 43.05 | 32.68 | 13.23 | |
Research & Development | - | - | - | 62.57 | 61.79 | 32.35 | |
Operating Expenses | 39.72 | 20.62 | 27.32 | 105.62 | 94.47 | 45.58 | |
Operating Income | -92.29 | -64.54 | -82.95 | -105.62 | -94.47 | -45.58 | |
Interest & Investment Income | 2.92 | 1.37 | 0.69 | 0.56 | 0.56 | 0.09 | |
Other Non Operating Income (Expenses) | -97.81 | -56.57 | -0.07 | - | - | - | |
EBT Excluding Unusual Items | -187.17 | -119.74 | -82.33 | -105.06 | -93.91 | -45.49 | |
Gain (Loss) on Sale of Investments | -0.14 | -0.03 | -0.18 | -0.52 | -0.05 | -0.02 | |
Pretax Income | -187.31 | -119.76 | -82.51 | -105.58 | -93.96 | -45.51 | |
Net Income | -187.31 | -119.76 | -82.51 | -105.58 | -93.96 | -45.51 | |
Net Income to Common | -187.31 | -119.76 | -82.51 | -105.58 | -93.96 | -45.51 | |
Shares Outstanding (Basic) | 131 | 84 | 38 | 26 | 22 | 13 | |
Shares Outstanding (Diluted) | 131 | 84 | 38 | 26 | 22 | 13 | |
Shares Change (YoY) | 89.66% | 122.72% | 47.77% | 16.53% | 71.19% | 134.01% | |
EPS (Basic) | -1.43 | -1.42 | -2.18 | -4.12 | -4.28 | -3.55 | |
EPS (Diluted) | -1.43 | -1.42 | -2.18 | -4.12 | -4.28 | -3.55 | |
Free Cash Flow | -81.84 | -55.17 | -78.09 | -90.73 | -78.21 | -36.31 | |
Free Cash Flow Per Share | -0.62 | -0.65 | -2.06 | -3.54 | -3.56 | -2.83 | |
Operating Margin | - | -645.80% | - | - | - | - | |
Profit Margin | - | -1198.47% | - | - | - | - | |
Free Cash Flow Margin | - | -552.12% | - | - | - | - | |
EBITDA | -92.28 | -64.53 | -82.95 | -105.62 | - | - | |
D&A For EBITDA | 0 | 0 | 0 | 0 | - | - | |
EBIT | -92.29 | -64.54 | -82.95 | -105.62 | -94.47 | -45.58 | |
Revenue as Reported | - | 9.99 | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.